188 related articles for article (PubMed ID: 29745092)
1. Therapeutic benefits of neoadjuvant and post-operative denosumab on sacral giant cell tumor: a retrospective cohort study of 30 cases.
Chen Z; Yang Y; Guo W; Yang R; Tang X; Yan T; Ji T; Xie L; Xu J; Wang J
J BUON; 2018; 23(2):453-459. PubMed ID: 29745092
[TBL] [Abstract][Full Text] [Related]
2. Clinical and pathological results of denosumab treatment for giant cell tumors of bone: Prospective study of 14 cases.
Deveci MA; Paydaş S; Gönlüşen G; Özkan C; Biçer ÖS; Tekin M
Acta Orthop Traumatol Turc; 2017 Jan; 51(1):1-6. PubMed ID: 27784623
[TBL] [Abstract][Full Text] [Related]
3. The risk of neurological deterioration while using neoadjuvant denosumab on patients with giant cell tumor of the spine presenting with epidural disease: a meta-analysis of the literature.
Al Farii H; McChesney G; Patel SS; Rhines LD; Lewis VO; Bird JE
Spine J; 2024 Jun; 24(6):1056-1064. PubMed ID: 38301904
[TBL] [Abstract][Full Text] [Related]
4. Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): For how long?
Palmerini E; Chawla NS; Ferrari S; Sudan M; Picci P; Marchesi E; Leopardi MP; Syed I; Sankhala KK; Parthasarathy P; Mendanha WE; Pierini M; Paioli A; Chawla SP
Eur J Cancer; 2017 May; 76():118-124. PubMed ID: 28324746
[TBL] [Abstract][Full Text] [Related]
5. Denosumab treatment of inoperable or locally advanced giant cell tumor of bone - Multicenter analysis outside clinical trial.
Rutkowski P; Gaston L; Borkowska A; Stacchiotti S; Gelderblom H; Baldi GG; Palmerini E; Casali P; Gronchi A; Parry M; Campanacci DA; Scoccianti G; Wagrodzki M; Ferrari S; Dijkstra S; Pieńkowski A; Grimer R
Eur J Surg Oncol; 2018 Sep; 44(9):1384-1390. PubMed ID: 29650420
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Local Recurrence in Giant-Cell Tumor of Bone Treated by Neoadjuvant Denosumab.
Chinder PS; Hindiskere S; Doddarangappa S; Pal U
Clin Orthop Surg; 2019 Sep; 11(3):352-360. PubMed ID: 31475058
[TBL] [Abstract][Full Text] [Related]
7. Preoperative denosumab treatment with curettage may be a risk factor for recurrence of giant cell tumor of bone.
Sano K; Suehara Y; Okubo T; Sasa K; Kurihara T; Akaike K; Kubota D; Torigoe T; Hasegawa N; Ishii M; Nakamura Y; Kim Y; Takagi T; Kaneko K; Hayashi T; Saito T
J Orthop Surg (Hong Kong); 2020; 28(2):2309499020929786. PubMed ID: 32539628
[TBL] [Abstract][Full Text] [Related]
8. Is a Short-course of Preoperative Denosumab as Effective as Prolonged Therapy for Giant Cell Tumor of Bone?
Hindiskere S; Errani C; Doddarangappa S; Ramaswamy V; Rai M; Chinder PS
Clin Orthop Relat Res; 2020 Nov; 478(11):2522-2533. PubMed ID: 32401001
[TBL] [Abstract][Full Text] [Related]
9. Giant cell tumor of the thoracic spine completely removed by total spondylectomy after neoadjuvant denosumab therapy.
Yonezawa N; Murakami H; Kato S; Takeuchi A; Tsuchiya H
Eur Spine J; 2017 May; 26(Suppl 1):236-242. PubMed ID: 28396950
[TBL] [Abstract][Full Text] [Related]
10. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone.
Branstetter DG; Nelson SD; Manivel JC; Blay JY; Chawla S; Thomas DM; Jun S; Jacobs I
Clin Cancer Res; 2012 Aug; 18(16):4415-24. PubMed ID: 22711702
[TBL] [Abstract][Full Text] [Related]
11. Ultra-Short Course of Neo-Adjuvant Denosumab for Nerve-Sparing Surgery for Giant Cell Tumor of Bone in Sacrum.
Liang H; Liu X; Yang Y; Guo W; Yang R; Tang X; Yan T; Li Y; Tang S; Li D; Qu H; Dong S; Ji T; Du Z; Zang J
Spine (Phila Pa 1976); 2022 May; 47(9):691-701. PubMed ID: 34961753
[TBL] [Abstract][Full Text] [Related]
12. Denosumab for the treatment of giant cell tumor of the bone.
Brodowicz T; Hemetsberger M; Windhager R
Future Oncol; 2015; 11(13):1881-94. PubMed ID: 26161925
[TBL] [Abstract][Full Text] [Related]
13. Objective tumor response to denosumab in patients with giant cell tumor of bone: a multicenter phase II trial.
Ueda T; Morioka H; Nishida Y; Kakunaga S; Tsuchiya H; Matsumoto Y; Asami Y; Inoue T; Yoneda T
Ann Oncol; 2015 Oct; 26(10):2149-54. PubMed ID: 26205395
[TBL] [Abstract][Full Text] [Related]
14. Risks and benefits of combining denosumab and surgery in giant cell tumor of bone-a case series.
Müller DA; Beltrami G; Scoccianti G; Campanacci DA; Franchi A; Capanna R
World J Surg Oncol; 2016 Nov; 14(1):281. PubMed ID: 27809843
[TBL] [Abstract][Full Text] [Related]
15. Denosumab treated giant cell tumour of bone: a morphological, immunohistochemical and molecular analysis of a series.
Girolami I; Mancini I; Simoni A; Baldi GG; Simi L; Campanacci D; Beltrami G; Scoccianti G; D'Arienzo A; Capanna R; Franchi A
J Clin Pathol; 2016 Mar; 69(3):240-7. PubMed ID: 26338802
[TBL] [Abstract][Full Text] [Related]
16. Histomorphometric Analysis of Pre- and Post-Denosumab-Treated Giant Cell Tumor of Bone.
Ud Din N; Umer M; Park YK
Int J Surg Pathol; 2020 Dec; 28(8):859-867. PubMed ID: 32429739
[No Abstract] [Full Text] [Related]
17. Challenges of denosumab in giant cell tumor of bone, and other giant cell-rich tumors of bone.
Lipplaa A; Dijkstra S; Gelderblom H
Curr Opin Oncol; 2019 Jul; 31(4):329-335. PubMed ID: 30844887
[TBL] [Abstract][Full Text] [Related]
18. Denosumab-treated giant cell tumor of bone. Its histologic spectrum and potential diagnostic pitfalls.
Roitman PD; Jauk F; Farfalli GL; Albergo JI; Aponte-Tinao LA
Hum Pathol; 2017 May; 63():89-97. PubMed ID: 28235628
[TBL] [Abstract][Full Text] [Related]
19. Denosumab Induces Neoplastic Stromal Cell Apoptosis
Chen X; Ye F; He H; Chen G; Chen Z; Ye E; He B; Yang Y; Zhang J
Curr Cancer Drug Targets; 2024; 24(5):565-578. PubMed ID: 37961860
[TBL] [Abstract][Full Text] [Related]
20. A new computerized tomography classification to evaluate response to Denosumab in giant cell tumors in the extremities.
Campanacci L; Sambri A; Medellin MR; Cimatti P; Errani C; Donati DM
Acta Orthop Traumatol Turc; 2019 Sep; 53(5):376-380. PubMed ID: 31253385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]